文献速递泌尿生殖与妇科肿瘤放疗

年轻与老年高危或极高危前列腺癌患者根治性放疗结局比较

Comparison of definitive radiotherapy outcomes between younger and older patients with high- or very-high-risk prostate cancer.
PubMed 文献 · Radiother Oncol · 2025-02-01

本研究比较569例高危或极高危前列腺癌患者接受根治性IMRT的肿瘤学结局,其中265例<75岁为A组、304例≥75岁为B组,采用倾向性评分匹配与竞争风险分析。匹配前A组7年BCFFS、DMFS、CFFS、OS优于B组,CSS无显著差异;匹配后除OS外各结局两组相当。竞争风险分析显示肿瘤特异性事件多见于A组,非肿瘤特异性事件多见于B组。

要点

  • 所有患者接受IMRT,每日2.2 Gy、共34次,总剂量74.8 Gy
  • 匹配前7年OS为A组87.4% vs B组68.6%(p<0.001)
  • 匹配后除OS外各肿瘤学结局两组相当,B组非肿瘤特异性事件占主导

核心结论

  • 倾向性评分匹配与竞争风险分析均提示,根治性IMRT可安全有效地用于老年高危或极高危前列腺癌患者,其肿瘤学结局与年轻患者相当。

研究设计与样本

  • 本研究纳入569例高危或极高危前列腺癌患者,其中A组265例年龄<75岁,B组304例年龄≥75岁。
  • 所有患者接受IMRT,每日2.2 Gy、共34次,总剂量74.8 Gy。
  • 采用倾向性评分匹配(全匹配法)平衡两组,并用竞争风险分析区分肿瘤特异性事件与非肿瘤特异性事件。

主要发现

  • 匹配前7年CSS为A组95.6% vs B组97.3%(p=0.704),两组无显著差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: This study aimed to compare the oncologic outcomes of definitive intensity-modulated radiotherapy (IMRT) between younger and older high- or very-high-risk prostate cancer patients using propensity score matching (PSM) and competing risk analysis (CRA). MATERIALS AND METHODS: A total of 569 patients were included in this analysis: 265 younger than 75 years (Group A) and 304 aged 75 years or above (Group B). All patients received IMRT with a daily fraction of 2.2 Gy, administered over 34 fractions, resulting in a total dose of 74.8 Gy. The primary outcomes included biochemical-failure-free survival (BCFFS), distant-metastasis-free survival (DMFS), clinical-failure-free survival (CFFS), cancer-specific survival (CSS), and overall survival (OS). PSM was used to balance the groups, employing a full matching method, while CRA distinguished between cancer-specific events and non-cancer-specific events. RESULTS: Before PSM, the 7-year BCFFS, DMFS, CFFS, CSS, and OS rates in Groups A and B were 83.0 % vs. 66.7 % (p = 0.011), 84.1 % vs. 68.0 % (p = 0.002), 82.1 % vs. 66.7 % (p = 0.008), 95.6 % vs. 97.3 % (p = 0.704), and 87.4 % vs. 68.6 % (p < 0.001), respectively. After PSM, the 7-year survival rates were comparable between both groups for all outcomes except OS. CRA revealed that cancer-specific events were more frequent in Group A, whereas non-cancer-specific events predominated in Group B. CONCLUSIONS: Both PSM and CRA indicated that definitive IMRT can be safely and effectively delivered to older patients with high- or very high-risk prostate cancer, achieving oncologic outcomes comparable to those in younger patients.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Kim YH, Jeong JU, Yang JH, et al. Comparison of definitive radiotherapy outcomes between younger and older patients with high- or very-high-risk prostate cancer. Radiother Oncol. 2025. PMID: 39894260. doi:10.1016/j.radonc.2025.110763

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。